Biogen Inc.
SYFOVRE
geographic atrophy secondary to age-related macular degeneration
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for SYFOVRE in geographic atrophy secondary to age-related macular degeneration are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“felzartamab, which is currently in Phase 3 studies for three kidney diseases with the first trial readout expected in the first half of 2027.”